Press Releases

Biogen Inc.announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currentl

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in the advanced or metastatic stage.1 C

Ecolab Life Sciences today announced it has launched an innovative new resin to help achieve cost savings and optimize operations throughout the antibody manufacturing process. Purolite™ AP+50 is an affinity chromatography resin with a 50-micron bead size offering the highest dynamic binding capacity of the AP resin platform while providing excellent durability for monoclonal antibody capture. It also leverages Ecolab’s patented Jetted resin bead manufacturing technology, an innov

Lisata Therapeutics, Inc.a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. (“GATC”), a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process. This collaboration builds on

BioAge Labs, Inc, a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway. Through its collaboration with Norwegian diagnostics company Age Labs AS [link], BioAge will profile more than 17,000 individual samples—collected over decades of aging from 6,000+ HUNT particip

Biotium, a leading provider of innovative fluorescent technologies for life science research, announces the release of the Glo-Plate™ White Photoactivation Device. This is a compact, LED-powered light box designed to develop DNA gels stained with DNAzure® Blue Nucleic Acid Gel Stain. Specifically created to empower educational labs and academic environments, the Glo-Plate™ White offers a cost-effective and user-friendly alternative to expensive DNA gel imaging system

Neurizon® Therapeutics Limited a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce new preclinical data demonstrating significant neuroprotective effects of NUZ-001 and its active metabolite, NUZ-001 Sulfone, in a zebrafish model of Huntington’s disease (HD). HD is a rare, inherited neurodegenerative disorder that causes progressive degeneration of motor function, cognition, and mental health.

Roche announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immu

Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two phase II trials and their open-label extensions, combined with the favourable safety

Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two phase II trials and their open-label extensions, combined with the favourable safety